Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Influenza

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 19 articles:
HTML format



Single Articles


    May 2020
  1. LIM JJ, Nilsson AC, Silverman M, Assy N, et al
    A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A infection.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00352.
    PubMed     Abstract available


  2. ADAMS SE, Lugovtsev VY, Kan A, Bovin NV, et al
    Laninamivir-Interferon-lambda1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly Than Laninamivir Alone.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00301.
    PubMed     Abstract available


    April 2020
  3. KOSHIMICHI H, Retout S, Cosson V, Duval V, et al
    Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00119.
    PubMed     Abstract available


  4. ZHAO L, Yan Y, Dai Q, Li X, et al
    Development of Novel Anti-influenza Thiazolides with Relatively Broad-spectrum Antiviral Potentials.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00222.
    PubMed     Abstract available


  5. NGUYEN CT, Suzuki S, Itoh Y, Ishigaki H, et al
    Efficacy of neuraminidase inhibitors against H5N6 highly pathogenic avian influenza virus in a non-human primate model.
    Antimicrob Agents Chemother. 2020 Apr 13. pii: AAC.02561.
    PubMed     Abstract available


    March 2020
  6. MARTINEZ MA
    Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
    Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399.
    PubMed     Abstract available


    September 2018
  7. FARRUKEE R, Zarebski AE, McCaw JM, Bloom JD, et al
    CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
    Antimicrob Agents Chemother. 2018 Sep 10. pii: AAC.01081.
    PubMed     Abstract available


    August 2018
  8. ALI SO, Takas T, Nyborg A, Shoemaker K, et al
    Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Antimicrob Agents Chemother. 2018 Aug 27. pii: AAC.00694.
    PubMed     Abstract available


    June 2018
  9. YOON JJ, Toots M, Lee S, Lee ME, et al
    Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
    Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00766.
    PubMed     Abstract available


    March 2018
  10. VIGIL A, Estelles A, Kauvar LM, Johnson SK, et al
    Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses.
    Antimicrob Agents Chemother. 2018 Mar 5. pii: AAC.02269.
    PubMed     Abstract available


    January 2018
  11. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".
    Antimicrob Agents Chemother. 2017;62.
    PubMed    


  12. HUNSBERGER S, Memoli MJ
    Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.
    Antimicrob Agents Chemother. 2017;62.
    PubMed    


    November 2017
  13. TSUJI BT, Fisher J, Boadi-Yeboah R, Holden PN, et al
    Azithromycin Pharmacodynamics against 'Persistent' Haemophilus influenza in Chronic Obstructive Pulmonary Disease.
    Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.01995.
    PubMed     Abstract available


    August 2017
  14. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Challenge Model: A Phase 2 Randomized Trial.
    Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.01154.
    PubMed     Abstract available


    May 2017
  15. LIM JJ, Derby MA, Zhang Y, Deng R, et al
    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00279.
    PubMed     Abstract available


    April 2017
  16. STAROSILA D, Rybalko S, Varbanetz L, Ivanskaya N, et al
    Anti-influenza activity of Bacillus subtilis probiotic strain.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00539.
    PubMed     Abstract available


  17. GAILLARD V, Galloux M, Garcin D, Eleouet JF, et al
    A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Abstract available


    March 2017
  18. GRIFFIN MP, Khan AA, Esser MT, Jensen K, et al
    Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Abstract available


    February 2017
  19. JONES JC, Marathe BM, Vogel P, Gasser R, et al
    The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.02460.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: